The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
MillerT.P., DahlbergS., CassadyJ.R.Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Eng J Med.1998; 339(1): 21–6.
KhaledH.M., ZekriZ.K., MokhtarN.A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: Long-term results. Ann Oncol.1999; 10(12): 1489–92.
4.
LinchD.C., HudsonB.V., HancockB.W.A randomized comparison of third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologocally aggressive non-hodgkin's lymphoma: A british national lymphoma investigation report. Br J Cancer.1996; 74: 318–22.
5.
SonneveldP., RidderM., van der LelieH.Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-hodgkin's lymphoma using COP versus CNOP chemotherapy. J Clin Oncol.1995; 10: 2530–9.
6.
MeyerR.M., BrowmanG.P., SamoshM.L.Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol.1995; 9: 2386–93.
7.
TirelliU., ErranteD., Van GlabbekeM.CHOP is the standard regimen in patients Ž 70 years of age with intermediate-grade and high-grade non-hodgkin's lymphoma: Results of a randomized study of the European organization for research and treatment of cancer lymphoma cooperative study group. J Clin Oncol.1998; 1: 27–34.
8.
LeeR., CabanillasF., BodeyG.P.A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. J Clin Oncol.1986; 4(10): 1455–61.
9.
VoseJ.M., LinkB.K., GrossbardM.L.Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol.2001; 19(2): 389–97.
10.
FisherR.I., GaynorE.R., DahlbergS.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med.1993; 328(14): 1002–6.
11.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–5.
12.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–9.
13.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56(8): 729–64.
14.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2000.Rockledge, PA: National Comprehensive Cancer Network; 2000.
15.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
16.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–7.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
21.
LymanG.H., BalducciL.Update of the economic analyses of the use of the colony-stimulating factors. Curr Opinion Hematol.1999; 6: 145–51.
22.
BalducciL., LymanG.H.Patients aged Ž 70 are at high risk for neutropenic infection and should receive hematopoietic growth factors when treated with moderately toxic chemotherapy [letter]. J Clin Oncol.2001; 19(5): 1583–5.
23.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–9.
24.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
25.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
26.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Source Book.2nd ed.Baltimore, MD: Williams and Wilkins;1996, 727–44.
27.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–90.
